All In Biotech

Drug Trial Radar · NCT07920783

A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of GLR2053 Tablets Following Single and Multiple Dose Administration, and the Effect of Food in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

Jul 30, 2027

Study completion Nov 9, 2027

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a high-fat meal on the pharmacokinetics of GLR2053.

Conditions

  • Atopic Dermatitis

Interventions

  • GLR2053 TabletsDrug

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GLR2053.

  • PlaceboDrug

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse events (AEs)Time frame: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
  2. The incidence of serious adverse events (SAEs)Time frame: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.